(Q33699902)

28 July 2017

1 reference

title

Optimal management of acute myocardial infarction at the dawn of the next millennium (English)

1 reference

acute myocardial infarction

28 July 2017

main subject

myocardial infarction

1 reference

based on heuristic

inferred from title

1 reference

Gersh BJ

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 August 1999

1 reference

28 July 2017

published in

American Heart Journal

1 reference

28 July 2017

volume

138

1 reference

28 July 2017

issue

2 Pt 2

1 reference

28 July 2017

page(s)

S188-202

1 reference

Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities.

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Thrombolysis for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm--paradoxic or predictable?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Do patients with left circumflex coronary artery-related acute myocardial infarction without ST-segment elevation benefit from reperfusion therapy?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptok

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Risk stratification and survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

The open-artery hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Quantification and time course of microvascular obstruction by contrast-enhanced echocardiography and magnetic resonance imaging following acute myocardial infarction and reperfusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Time as an Adjunctive Agent to Thrombolytic Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

The physician's role in minimizing prehospital delay in patients at high risk for acute myocardial infarction: recommendations from the National Heart Attack Alert Program. Working Group on Educational Strategies To Prevent Prehospital Delay in Pati

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A comparison of reteplase with alteplase for acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Deleterious effects of a systemic lytic state on reperfused myocardium. Minimization of reperfusion injury and enhanced recovery of myocardial function by direct angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Dangers of delay of initiation of either thrombolysis or primary angioplasty in acute myocardial infarction with increasing use of primary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Primary stenting in acute myocardial infarction: the promise and the proof

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myoca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Comparison of primary angioplasty versus thrombolytic therapy for acute myocardial infarction. Alabama Registry of Myocardial Ischemia Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Long-term implications of reocclusion on left ventricular size and function after successful thrombolysis for first anterior myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Current issues in reperfusion therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coron

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Acute coronary syndromes: unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. A preliminary clinical report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiológicos Latinoamérica) Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

The role of magnesium therapy in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Timing of Magnesium Therapy Affects Experimental Infarct Size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Magnesium in acute myocardial infarction: overview of available evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Intravenous diltiazem in acute myocardial infarction. Diltiazem as adjunctive therapy to activase (DATA) trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Ten years of benefit from a one-hour intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

Time to treatment of acute myocardial infarction revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2899%2970342-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-8703(99)70342-X

1 reference

28 July 2017

1 reference